Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program With DPX-Survivac in Ovarian ...
HALIFAX, NOVA SCOTIA -- (Marketwired) -- 08/25/16 -- Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced new data from its Phase 1/1b trial in ovarian cancer, which reinforced previously reported …